157 related articles for article (PubMed ID: 27560456)
1. A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers.
Chen X; Liu D; Wu Y; Song H; Liu Y; Jiang J; Hu P
Xenobiotica; 2017 Jul; 47(7):592-599. PubMed ID: 27560456
[TBL] [Abstract][Full Text] [Related]
2. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
5. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Duchin K; Duggal A; Atiee GJ; Kidokoro M; Takatani T; Shipitofsky NL; He L; Zhang G; Kakkar T
Clin Pharmacokinet; 2018 Feb; 57(2):221-228. PubMed ID: 28512699
[TBL] [Abstract][Full Text] [Related]
6. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
[TBL] [Abstract][Full Text] [Related]
7. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.
Mendell J; Tachibana M; Shi M; Kunitada S
J Clin Pharmacol; 2011 May; 51(5):687-94. PubMed ID: 20534818
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
Mendell J; Noveck RJ; Shi M
Br J Clin Pharmacol; 2013 Apr; 75(4):966-78. PubMed ID: 22924409
[TBL] [Abstract][Full Text] [Related]
9. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Parasrampuria DA; Weilert D; Maa JF; Dishy V; Kochan J; Shi M; Brown KS
Clin Drug Investig; 2016 Feb; 36(2):127-36. PubMed ID: 26597179
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.
Yin OQ; Miller R
Clin Drug Investig; 2014 Oct; 34(10):743-52. PubMed ID: 25186833
[TBL] [Abstract][Full Text] [Related]
12. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Mendell J; Chen S; He L; Desai M; Parasramupria DA
Clin Drug Investig; 2015 Jul; 35(7):447-53. PubMed ID: 26068927
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation - The Prospective KYU-RABLE Study.
Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Matsumoto T; Origasa H; Okumura K;
Circ J; 2019 Sep; 83(10):2017-2024. PubMed ID: 31511436
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Parasrampuria DA; Truitt KE
Clin Pharmacokinet; 2016 Jun; 55(6):641-55. PubMed ID: 26620048
[TBL] [Abstract][Full Text] [Related]
15. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Mendell J; Johnson L; Chen S
J Clin Pharmacol; 2015 Dec; 55(12):1395-405. PubMed ID: 26011596
[TBL] [Abstract][Full Text] [Related]
16. Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).
Suzuki S; Morishima Y; Takita A; Yagi N; Otsuka T; Arita T; Yamashita T
Heart Vessels; 2019 Dec; 34(12):2011-2020. PubMed ID: 31123819
[TBL] [Abstract][Full Text] [Related]
17. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
[TBL] [Abstract][Full Text] [Related]
18. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban.
Ansell JE; Bakhru SH; Laulicht BE; Steiner SS; Grosso MA; Brown K; Dishy V; Lanz HJ; Mercuri MF; Noveck RJ; Costin JC
Thromb Haemost; 2017 Jan; 117(2):238-245. PubMed ID: 27853809
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Zahir H; Matsushima N; Halim AB; He L; Zhang G; Lee F; Worland V; Mendell J
Thromb Haemost; 2012 Jul; 108(1):166-75. PubMed ID: 22628060
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
AlHajri L; Jabbari S; AlEmad H; AlMahri K; AlMahri M; AlKitbi N
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):230-238. PubMed ID: 27811198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
